Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended its research and d…
. Heidelberg Pharma präsentiert initiale Ergebnisse der ersten klinischen Studie mit dem ATAC®-Kandidaten HDP-101 Lize…
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threaten…
Finding the right eClinical provider can be difficult, especially for a young clinical research organization working wit…
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threaten…
Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended and broadened its…
– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Su…
. – IMU- 935 Has Been Observed In Vitro to Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokines Withou…